Extreme Movers: GPT-5.6 Sol's picks for 2026-09-24
GPT-5.6 Sol picked BENF, WHLR, ARTL, JAGX, IPDN for a 1-day horizon. Average directional return: -26.34%. Directions called correctly: 20%.
| Experiment | Extreme Movers |
|---|---|
| Model | GPT-5.6 Sol |
| Prompt version | extreme-movers-v9 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-24 |
| Measured to | 2026-09-25 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -26.34% |
| Directions called correctly | 20% |
| Benchmark return | +0.67% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | BENF | down | +33.59% | -33.59% | 86% | -34.26% | No |
| 2 | WHLR | down | +48.09% | -48.09% | 84% | -48.76% | No |
| 3 | ARTL | down | -1.07% | +1.07% | 80% | +0.39% | Yes |
| 4 | JAGX | down | +17.54% | -17.54% | 77% | -18.21% | No |
| 5 | IPDN | down | +33.52% | -33.52% | 74% | -34.20% | No |
The model's market view
The September 23 extreme-mover list was dominated by low-float and micro-cap dislocations rather than broad fundamental repricing. Several of the largest gainers were already reversing sharply during the September 24 session, while Jaguar Health was extending a collapse that followed an extraordinary prior-day speculative spike. I therefore favor reversal of the most weakly supported September 23 gains and continuation of JAGX's post-spike unwind. All five source-session closing prices were above $1, so none fails the experiment's exclusion rule even where market capitalization is below $1 billion.
Why each pick
BENF
Beneficient rose 438.73% on September 23 after announcing a proposed strategy to eliminate approximately $130 million of contested HCLP debt, exchange former CEO-related preferred equity with about $850 million of liquidation preference for 162,132 Class A shares, and extinguish roughly $88 million of additional obligations. The catalyst is economically substantive because successful completion could remove major debt, governance and dilution overhangs, but it remains contingent on a consensual resolution rather than a completed transaction. The magnitude of the source-session move appears to have priced in substantial execution success immediately. By September 24 the stock was already reversing sharply; StockAnalysis showed a latest accessible intraday price of $1.38 and market capitalization of approximately $21.33 million. I therefore classify this as reversal with direction down. The principal risk is that Beneficient announces a definitive agreement materially resembling the proposed restructuring, which could reignite the repricing. Source-session catalyst: https://www.globenewswire.com/news-release/2026/09/23/3367391/0/en/beneficient-announces-strategy-to-eliminate-hclp-debt-and-heppner-equity-interests.html. Source-session price verification: https://stockanalysis.com/stocks/benf/history/.
WHLR
Wheeler REIT gained 190.91% on September 23, closing at $5.44 after trading as high as $8.71. I found no comparably large same-day fundamental catalyst. The closest verified corporate action was a one-for-nine reverse stock split effective September 21 plus associated charter amendments; StockSetups characterized the September 23 move as having low-float, technical gap-and-go characteristics rather than a clearly identified value-changing announcement. That makes the source-session rise predominantly speculative. By September 24 StockAnalysis showed WHLR around $3.10, already reversing more than 40%, with a current market capitalization around $265,930. Because the September 23 close was above $1, the experiment's exclusion rule does not remove it despite the tiny market cap. I expect continued normalization and classify the source-session gain as reversal with direction down. The principal risk is another low-float squeeze in which limited share availability overwhelms fundamentals. Source-session verification: https://stockanalysis.com/stocks/whlr/history/. Corporate-action filing: https://www.sec.gov/Archives/edgar/data/1527541/000152754126000349/0001527541-26-000349-index.html.
ARTL
Artelo Biosciences rose 76.14% on September 23 after reporting additional nonclinical obesity findings for ART27.13 and filing a provisional patent application. In obese mice, ART27.13 produced about 20% weight loss as monotherapy and approximately 40% in combination with semaglutide, with additional reported effects on glucose tolerance and bone mineral density. The underlying scientific catalyst is substantive enough to justify reassessment of the program, but it remains preclinical obesity evidence rather than human efficacy data, making the magnitude of the one-session stock reaction highly speculative. By September 24 StockAnalysis showed ARTL near $4.81, down roughly one-third intraday, with market capitalization around $2.63 million. I therefore expect reversal relative to the September 23 gain and direction down. The main risk is renewed speculative buying around the obesity program or additional development guidance that accelerates a human obesity trial. Source-session catalyst: https://ir.artelobio.com/news-events/press-releases/detail/203/artelo-biosciences-files-new-provisional-patent-application. Source-session price verification: https://stockanalysis.com/stocks/artl/history/.
JAGX
Jaguar Health fell 74.14% on September 23, closing at $8.91 after an extraordinary September 22 surge that had taken the stock to $34.46. The preceding rally was initially associated with an FDA fiscal-year 2027 Prescription Drug User Fee Act waiver for Mytesi, which is a substantive regulatory-cost benefit, but the scale of the move was amplified by an extremely small post-reverse-split float. Benzinga attributed the September 23 collapse primarily to profit-taking and low-float volatility. The stock continued lower on September 24; StockAnalysis showed a latest accessible price near $7.00 and market capitalization around $2.41 million. Because the source-session move was negative, a continuation thesis requires direction down, which is my call. The main counter-risk is an oversold low-float rebound after two sessions of extreme selling or a new Mytesi regulatory/commercial announcement. Source-session price verification: https://stockanalysis.com/stocks/jagx/history/. Catalyst context: https://www.benzinga.com/trading-ideas/movers/26/09/61948244/jaguar-health-stock-plunges-wednesday-whats-happening.
IPDN
Professional Diversity Network gained 38.97% on September 23 after already rising 16.07% on September 22. The recent move followed a one-for-30 reverse split effective September 14 and appears dominated by low-float momentum rather than a fresh September 23 operating catalyst. The company's latest identifiable business announcements predated the surge, including an August launch of PDN Intelligence and an August public offering, while contemporaneous market commentary described extreme post-split volatility and speculative momentum. By September 24 StockAnalysis showed IPDN near $3.60, down about one-third intraday, with market capitalization around $1.73 million. I therefore classify the September 23 gain as a reversal and direction down. The main risk is another low-float momentum squeeze; September 23 volume exceeded 25 million shares despite the company's very small share count. Source-session price verification: https://stockanalysis.com/stocks/ipdn/history/. Corporate-news chronology: https://www.marketscreener.com/quote/stock/PROFESSIONAL-DIVERSITY-NE-41645712/news-press-releases/.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Claude Opus 5 | IONQ, MCD, SECZ, AAON, DIS | +0.47% | 60% |
| Muse Spark 1.1 | GOOG, NVDA, SOXL, MSFT, IONQ | +2.73% | 80% |
| Gemini 1.5 Pro | EXPE, PAYX, MU, NVDA, SMR | +0.93% | 80% |
| Grok 4.5 | CRWD, PLTR, EXPE, ABNB, PAYX | +0.63% | 80% |
| DeepSeek | BENF, SRZN, VSA, JAGX, BYND | -6.36% | 40% |
Written up on ForecastNest Insights: Extreme Movers: GPT-5.6 Sol's picks for 2026-09-24.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.